<DOC>
	<DOCNO>NCT02457520</DOCNO>
	<brief_summary>This uncontrolled , open-label study conduct approximately 200 healthy male , non-pregnant , non-nursing female , age 12 45 year , severe recalcitrant nodular acne . ABSORICA® ( isotretinoin ) capsule 0.5 mg/kg/day administer 4 week follow 1.0 mg/kg/day 16 week . Female subject consent use two form birth control abstinence include .</brief_summary>
	<brief_title>ABSORICA Patients With Severe Recalcitrant Nodular Acne</brief_title>
	<detailed_description>This study design collect efficacy , safety , quality life ( QOL ) data subject receive Absorica® without food . The study investigate treatment efficacy , frequency relapse treatment discontinue , quality life active treatment 2-year post treatment period overall safety treatment Absorica® . This single-arm , open-label study consist 2 phase : 20-week ( 5-month ) open-label Active Treatment Period ( ATP ) 104-week ( 2-year ) post treatment period ( PTP ) . The total study duration 124 week , exclude screening period . During ATP , week 2 visit , visit schedule 4-week interval total 8 visit ( 1 screen visit , 1 baseline visit , 6 on-study visit ) . During PTP , first visit 4 week End Treatment ( EOT ) , second visit 12 week EOT , subsequent visit schedule 26-week ( ± 2 week ) interval total 6 visit .</detailed_description>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>General Inclusion Criteria Subjects must meet following mandatory inclusion criterion time screen eligible enter study must agree conform requirement study iPLEDGE program . Written informed consent , include mandatory photographic consent , genderspecific inform consent form ( ICF ) &amp; Health Insurance Portability Accountability Act ( HIPAA ) authorization prior performance studyrelated procedure . Pregnant female females become pregnant ATP phase trial 30 day receive last dose study drug . Female subject childbearing potential ready use 2 form effective contraception simultaneously 1 month start Absorica® ( isotretinoin ) , take Absorica® &amp; 1 month Absorica® stop . Male female subject nonchildbearing potential Specific Severe recalcitrant nodular acne . Five nodule lesion face . Treatmentnaïve subject . Age 12 45 year . Weight 40 110 kg . Female subject childbearing potential : Negative result serum pregnancy test sensitivity least 25 milliinternational unit/mL . Good general health determine investigator base subject 's medical history , physical examination , vital sign measurement , laboratory test result . Subjects present stable &amp; control diabetes mellitus ( Types I II ) . Subjects previously diagnose polycystic ovarian syndrome ( PCOS ) include study opinion investigator clinically significant abnormality ( eg , metabolic syndrome elevate lipid General Exclusion Criteria Presence clinically significant physical examination finding , vital sign measurement , abnormal laboratory value ; Presence beard facial hair could interfere study assessment ; Participated another clinical trial receive investigational product within 3 month prior screen ; History excessive suspect abuse alcohol ( base clinical judgment investigator ) , recreational drug , and/or drug abuse , e.g. , club drug , cocaine , ecstasy/MDMA ( methylenedioxymethamphetamine ) , heroin , inhalant , marijuana , methamphetamine , phencyclidine , prescription medication , anabolic steroid , etc . Use prohibit restricted prior concomitant medication . Female Specific Exclusion Criteria Are pregnant ; Are high risk become pregnant likely become pregnant treatment ; Are breastfeed consider breastfeed course study ; Have know history PCOS another clinically significant abnormality ( eg , metabolic syndrome elevate lipid ) ; Are unable unwilling maintain compliance birth control measure</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>